Transgene Overview

  • Year Founded
  • 1979

Year Founded

  • Status
  • Public

  • Employees
  • 160

Employees

  • Stock Symbol
  • TNG

Stock Symbol

  • Investments
  • 4

  • Share Price
  • $0.80
  • (As of Friday Closing)

Transgene General Information

Description

Transgene SA is a biotechnology company that designs and develops virus based immunotherapy products focused on the development of individualized therapeutic vaccines against cancers. The flagship program, TG4050, is an individualized therapeutic vaccine based on the myvac platform. The company also has other viral vector-based programs, including BT-001, an oncolytic virus based on the Invir.IO viral backbone, which is in clinical development. In addition, it conducts discovery and preclinical work, aimed at developing novel immunotherapies.

Contact Information

Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • 400 Boulevard Gonthier d'Andernach
  • Parc dInnovation - CS80166
  • 67405 Illkirch-Graffenstaden
  • France
+33 03
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
PAR
Corporate Office
  • 400 Boulevard Gonthier d'Andernach
  • Parc dInnovation - CS80166
  • 67405 Illkirch-Graffenstaden
  • France
+33 03

Transgene Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Transgene Stock Performance

As of 13-Nov-2026, Transgene’s stock price is $0.80. Its current market cap is $222M with 278M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.80 $0.81 $0.75 - $1.57 $222M 278M 118K -$0.20

Transgene Financials Summary

As of 30-Jun-2026, Transgene has a trailing 12-month revenue of $807K.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 102,630 323,004 77,762 146,798
Revenue 807 553 332 1,569
EBITDA (37,528) (39,274) (33,477) (22,278)
Net Income (39,543) (42,327) (36,760) (24,161)
Total Assets 142,197 163,068 43,885 49,983
Total Debt 0 0 18 1,389
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Transgene Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Transgene‘s full profile, request access.

Request a free trial

Transgene Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Transgene SA is a biotechnology company that designs and develops virus based immunotherapy products focused on the deve
Drug Discovery
Illkirch-Graffenstaden, France
160 As of 2026

Cambridge, MA
 

Lexington, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Transgene Competitors (44)

One of Transgene’s 44 competitors is Moderna, a Formerly VC-backed company based in Cambridge, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Moderna Formerly VC-backed Cambridge, MA
Agenus Formerly VC-backed Lexington, MA
Innate Pharma Formerly VC-backed Marseille, France
TME Pharma Formerly VC-backed Berlin, Germany
Arcus Biosciences Formerly VC-backed Hayward, CA
You’re viewing 5 of 44 competitors. Get the full list »

Transgene Patents

Transgene Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026041811-A1 Recombinant poxvirus and method for regulating the expression of toxic conditional gene products of said recombinant poxvirus in a producing cell Pending 23-Aug-2024
WO-2024062098-A1 Recombinant pseudocowpox virus encoding an interleukin-12 Inactive 23-Sep-2022
AU-2023326730-A1 Chimeric poxviruses Pending 18-Aug-2022
EP-4573113-A1 Chimeric poxviruses Pending 18-Aug-2022
JP-2025528219-A Chimeric poxviruses Pending 18-Aug-2022 C12N7/00
To view Transgene’s complete patent history, request access »

Transgene Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Transgene Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Transgene‘s full profile, request access.

Request a free trial

Transgene Investments (4)

Transgene’s most recent deal was a PE Growth/Expansion with Tasly Biopharmaceuticals for . The deal was made on 28-Jun-2019.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Tasly Biopharmaceuticals 28-Jun-2019 PE Growth/Expansion Drug Discovery
Tasly Biopharmaceuticals 01-Jul-2018 Corporate Drug Discovery
Active Biomarkers 01-Jan-2011 Joint Venture Laboratory Services (Healthcare)
Transgene Tasly (Tianjin) BioPharmaceutical 01-Jan-2010 Joint Venture Pharmaceuticals
To view Transgene’s complete investments history, request access »

Transgene ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

30.67 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Transgene’s complete esg history, request access »

Transgene Exits (2)

Transgene’s most recent exit was on 01-Jan-2011 from Active Biomarkers. The exit was categorized as with 2 buyers.

Company Name Exit Date Exit Type Exit Size Status Buyers
Active Biomarkers 01-Jan-2011 Completed
  • 2 buyers
Transgene Tasly (Tianjin) BioPharmaceutical 01-Jan-2010 Joint Venture Completed
  • 2 buyers
To view Transgene’s complete exits history, request access »

Transgene FAQs

  • When was Transgene founded?

    Transgene was founded in 1979.

  • Where is Transgene headquartered?

    Transgene is headquartered in Illkirch-Graffenstaden, France.

  • What is the size of Transgene?

    Transgene has 160 total employees.

  • What industry is Transgene in?

    Transgene’s primary industry is Drug Discovery.

  • Is Transgene a private or public company?

    Transgene is a Public company.

  • What is Transgene’s stock symbol?

    The ticker symbol for Transgene is TNG.

  • What is the current stock price of Transgene?

    As of 13-Nov-2026 the stock price of Transgene is $0.80.

  • What is the current market cap of Transgene?

    The current market capitalization of Transgene is $222M.

  • What is Transgene’s current revenue?

    The trailing twelve month revenue for Transgene is $807K.

  • Who are Transgene’s competitors?

    Moderna, Agenus, Innate Pharma, TME Pharma, and Arcus Biosciences are some of the 44 competitors of Transgene.

  • What is Transgene’s annual earnings per share (EPS)?

    Transgene’s EPS for 12 months was -$0.20.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process